BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23409060)

  • 21. Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator.
    Guo Y; Ferdani R; Anderson CJ
    Bioconjug Chem; 2012 Jul; 23(7):1470-7. PubMed ID: 22663248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ImmunoPET Imaging of α
    White JB; Hu LY; Boucher DL; Sutcliffe JL
    Mol Imaging Biol; 2018 Feb; 20(1):103-113. PubMed ID: 28653240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
    Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
    J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved Immuno-PET Imaging of HER2-Positive Tumors in Mice: Urokinase Injection-Triggered Clearance Enhancement of
    Ren Q; Mohri K; Warashina S; Wada Y; Watanabe Y; Mukai H
    Mol Pharm; 2019 Mar; 16(3):1065-1073. PubMed ID: 30633529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and Evaluation of New Bifunctional Chelators with Phosphonic Acid Arms for Gallium-68 Based PET Imaging in Melanoma.
    Gai Y; Sun L; Lan X; Zeng D; Xiang G; Ma X
    Bioconjug Chem; 2018 Oct; 29(10):3483-3494. PubMed ID: 30205001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
    Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
    J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.
    Kumar SR; Gallazzi FA; Ferdani R; Anderson CJ; Quinn TP; Deutscher SL
    Cancer Biother Radiopharm; 2010 Dec; 25(6):693-703. PubMed ID: 21204764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival.
    Hathi D; Chanswangphuwana C; Cho N; Fontana F; Maji D; Ritchey J; O'Neal J; Ghai A; Duncan K; Akers WJ; Fiala M; Vij R; DiPersio JF; Rettig M; Shokeen M
    Sci Rep; 2022 Jan; 12(1):30. PubMed ID: 34996933
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Ocak M; Beaino W; White A; Zeng D; Cai Z; Anderson CJ
    Cancer Biother Radiopharm; 2018 Mar; 33(2):74-83. PubMed ID: 29634417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.
    Michigami T; Shimizu N; Williams PJ; Niewolna M; Dallas SL; Mundy GR; Yoneda T
    Blood; 2000 Sep; 96(5):1953-60. PubMed ID: 10961900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
    Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
    J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).
    Shokeen M; Anderson CJ
    Acc Chem Res; 2009 Jul; 42(7):832-41. PubMed ID: 19530674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
    Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
    Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting VPAC1 Receptors for Imaging Glioblastoma.
    Tripathi SK; Kean R; Bongiorno E; Hooper DC; Jin YY; Wickstrom E; McCue PA; Thakur ML
    Mol Imaging Biol; 2020 Apr; 22(2):293-302. PubMed ID: 31292914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enantiopure bifunctional chelators for copper radiopharmaceuticals--does chirality matter in radiotracer design?
    Singh AN; Dakanali M; Hao G; Ramezani S; Kumar A; Sun X
    Eur J Med Chem; 2014 Jun; 80():308-15. PubMed ID: 24793881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer.
    Wuest M; Trayner BJ; Grant TN; Jans HS; Mercer JR; Murray D; West FG; McEwan AJ; Wuest F; Cheeseman CI
    Nucl Med Biol; 2011 May; 38(4):461-75. PubMed ID: 21531283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
    Qi S; Hoppmann S; Xu Y; Cheng Z
    Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin.
    Jiang L; Kimura RH; Miao Z; Silverman AP; Ren G; Liu H; Li P; Gambhir SS; Cochran JR; Cheng Z
    J Nucl Med; 2010 Feb; 51(2):251-258. PubMed ID: 20124048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Use of PET Imaging for Prognostic Integrin α
    Huang CW; Hsieh WC; Hsu ST; Lin YW; Chung YH; Chang WC; Chiu H; Lin YH; Wu CP; Yen TC; Huang FT
    Theranostics; 2017; 7(16):4013-4028. PubMed ID: 29109795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.